Physician profile
David A Campbell
NPI 1023109345
$11,011.63
in general payments reported to CMS, 2019-2025
33 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $659 · 2021: $1,873 · 2022: $2,311 · 2023: $1,788 · 2024: $2,200 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,413.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,569.43 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $2,143.07 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $719.70 | 2019-2025 | |
| Intuitive Surgical, INC. | $571.50 | 2022 | |
| Stryker Corporation | $559.33 | 2019-2022 | |
| Janssen Biotech, INC. | $539.06 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $383.34 | 2019-2023 | Taltz |
| Pfizer INC. | $330.30 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $328.81 | 2021-2024 | Acthar |
| Ucb, INC. | $324.22 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $322.00 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $273.65 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $241.55 | 2019-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.99 | 2019-2024 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $209.63 | 2022-2024 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $175.20 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $165.06 | 2019-2024 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $138.04 | 2021-2025 | Opsumit, Uptravi |
| Sobi, INC | $126.58 | 2022-2025 | |
| Genzyme Corporation | $114.21 | 2021-2025 | |
| Genentech USA, INC. | $104.03 | 2019-2024 | Actemra |
| Organon LLC | $87.15 | 2023-2024 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $67.31 | 2019 | |
| Pacira Therapeutics, INC. | $60.08 | 2019-2020 | |
| Pharming Healthcare, INC. | $54.06 | 2023-2024 | Ruconest |
| Celgene Corporation | $35.80 | 2019 | |
| Ibsa Pharma INC. | $35.64 | 2023-2024 | Tirosint, Licart, Tirosint |
| Regeneron Healthcare Solutions, INC. | $30.50 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.45 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $15.08 | 2019 | |
| Octapharma USA, INC. | $14.26 | 2022 | |
| Hollister Incorporated | $14.16 | 2023 | New Image, Adapt Ceraring |
| Antares Pharma, INC. | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.